PEC EnCap

Drug Profile

PEC EnCap

Alternative Names: Allogeneic stem cell therapy - ViaCyte; Encapsulated human islet cell therapy - ViaCyte; Encapsulated islet cell transplantation therapy - ViaCyte; Encapsulated pancreatic cell therapy - ViaCyte; Encapsulated pancreatic cell transplantation therapy - ViaCyte; Pancreatic beta cell replacement therapy - ViaCyte; PEC-EnCap; PEC-Encap™; Pro-Islet; VC-01

Latest Information Update: 23 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ViaCyte Inc
  • Class Stem cell therapies
  • Mechanism of Action Pancreatic beta cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Type 1 diabetes mellitus
  • Preclinical Type 2 diabetes mellitus

Most Recent Events

  • 17 Apr 2018 Viacyte has patent protection for Stem Cell-Derived Cell Replacement Therapies in Europe, USA, Japan, China, Hong Kong, Singapore, South Korea and Australia
  • 24 Apr 2017 Preclinical trials in Type-2 diabetes mellitus in USA (SC) before April 2017
  • 29 Mar 2017 ViaCyte and W. L. Gore & Associates collaborate to develop novel implantable delivery technologies for cell therapies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top